Piper Jaffray Starts Fulgent Genetics (FLGT) at Overweight

Go back to Piper Jaffray Starts Fulgent Genetics (FLGT) at Overweight

BTIG Starts Fulgent Genetics (FLGT) at Buy

October 24, 2016 7:32 AM EDT

BTIG initiated coverage on Fulgent Genetics (NASDAQ: FLGT) with a Buy rating and a price target of $15.

Analyst Karen Koski said, "While the genetic testing market is not without challenges and competition is formidable, we believe Fulgents proprietary technology platform drives multiple sustainable... More

Credit Suisse Starts Fulgent Genetics (FLGT) at Outperform

October 24, 2016 6:30 AM EDT

Credit Suisse initiates coverage on Fulgent Genetics (NASDAQ: FLGT) with a Outperform rating and a price target of $13.00.

Analyst Erin Wilson commented, "FLGT is a rapidly-growing genetic testing company, leveraging a proprietary technology platform to provide physicians with relevant diagnostic information. Its analytics platform... More